Embargo Policy

Full text of accepted abstracts will be made available to media registrants on April 8, 2024, two weeks before the content goes live to the public. Abstracts will be released to the public on April 22, 2024 at 4:30pm ET.

Researchers and presenters are free to discuss the content of their abstracts throughout this embargo period, but any abstract-related content may not be published until the abstracts are publicly released online. 

Updated data, new graphics, and follow-up information to be presented during oral presentation sessions is embargoed until 6 a.m. on the presentation day. 

ASGCT will publish the titles and authors in the abstract collection upon the acceptance of notification. After an abstract author has accepted their presentation role, the author and their organization are encouraged to publicize the title, author name, and presentation time across any channels they'd like, tagging ASGCT where applicable.

Audio Recording, Video Recording, Photography, and Distribution of Presentations and Slides

Attendees and media registrants are required to abide by any recording, photography, or screen capture requests made by speakers at any ASGCT event.

Photography and recording for personal reference is allowed. However, attendees and media registrants may not share or republish any materials from ASGCT events, including but not limited to slides, unpublished data, or presentation materials, without explicit written permission from both the presenter and ASGCT.

Copyright Ownership

Authors assign copyright of the abstract to ASGCT upon submission, unless one of the authors is a U.S. Federal Employee. This means that encore or identical abstracts may not be republished or submitted to another meeting. ASGCT has no copyright over additional information shared in the oral or poster presentation which is not in the abstract.

Publication Exceptions

In exceedingly rare circumstances, ASGCT may grant an exception to the embargo policy in order to comply with regulations from the Securities and Exchange Commission (SEC), other federal law, or international law.

Any exception request must be submitted to ASGCT in writing to CEO David Barrett (dbarrett@asgct.org), Senior Program Manager Alex Peterson (apeterson@asgct.org), Program Manager Kim Durham (kdurham@asgct.org) and Director of Communications Alex Wendland (awendland@asgct.org) at least 48 hours before the conclusion of the public embargo, and must include the following:

Statement that an exception is required to abide by applicable securities laws
Statement that the disclosed information is the absolute minimum necessary to comply with the applicable securities law
The lead author and presenter (both if they are different) copied on any correspondence
Signature of legal counsel

Whenever possible, ASGCT prefers any disclosure follow these guidelines:

Do not include implications or translational interpretations of results
Necessary data presented in qualitative terms rather than quantitative terms
Include the submission to and upcoming presentation at the ASGCT Annual Meeting

For example, a press release stating “we’re hopeful that the research presented at the ASGCT Annual Meeting will bring gene therapy for [insert disease] closer to the clinic, and we’re excited to share additional updates during our presentation,” is a qualitative statement and preferred in the case of an exception. However, a statement such as “in the study submitted to ASGCT, 5 of 7 patients demonstrate no disease symptoms and we’ve applied for FDA fast track designation,” is a quantitative statement and should not be included in a release.